- Home
- ERAS vs STK Comparison
ERAS vs STK Comparison
Compare ERAS & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- STK
- Stock Information
- Founded
- ERAS 2018
- STK 2009
- Country
- ERAS United States
- STK United States
- Employees
- ERAS N/A
- STK N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- ERAS Health Care
- STK Finance
- Exchange
- ERAS Nasdaq
- STK Nasdaq
- Market Cap
- ERAS 396.6M
- STK 434.6M
- IPO Year
- ERAS 2021
- STK N/A
- Fundamental
- Price
- ERAS $1.39
- STK $28.58
- Analyst Decision
- ERAS Strong Buy
- STK
- Analyst Count
- ERAS 6
- STK 0
- Target Price
- ERAS $4.83
- STK N/A
- AVG Volume (30 Days)
- ERAS 1.4M
- STK 38.2K
- Earning Date
- ERAS 05-20-2025
- STK 01-01-0001
- Dividend Yield
- ERAS N/A
- STK 6.60%
- EPS Growth
- ERAS N/A
- STK N/A
- EPS
- ERAS N/A
- STK N/A
- Revenue
- ERAS N/A
- STK N/A
- Revenue This Year
- ERAS N/A
- STK N/A
- Revenue Next Year
- ERAS N/A
- STK N/A
- P/E Ratio
- ERAS N/A
- STK N/A
- Revenue Growth
- ERAS N/A
- STK N/A
- 52 Week Low
- ERAS $1.01
- STK $24.95
- 52 Week High
- ERAS $3.45
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- ERAS 51.46
- STK 59.09
- Support Level
- ERAS $1.37
- STK $27.85
- Resistance Level
- ERAS $1.61
- STK $28.75
- Average True Range (ATR)
- ERAS 0.14
- STK 0.49
- MACD
- ERAS 0.00
- STK 0.27
- Stochastic Oscillator
- ERAS 45.68
- STK 94.94
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.